CompletedNot Applicable

Combined Use of a Novel Cardioplegic Formula With MPS® Versus Cardioplexol ® in Urgent Isolated CABG Using MiECC in Patients With Recent Acute Myocardial Infarction

Switzerland307 participantsStarted 2010-02-01

Plain-language summary

The goal of this study is to compare the two cardioplegia solutions (blood cardioplegia by means of MPS ® vs. Cardioplexol ®) regarding perioperative outcome and with special attention to cardiac markers in patients with a recent heart attack.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who underwent a CABG using MPS® or Cardioplexol ® * Heart attack less than 7 days before surgery Exclusion Criteria: * use of other cardioplegia solution than Cardioplexol ® or MPS® * other inventions than CABG * explicit will of the patient that his data may not be used * denied general consent

What they're measuring

myocardial damage

Timeframe: patients with that received a coronary artery bypass grafting and that were treated (for approximately 15 days) at the University Hospital between February 2010 and January 2020 (data taken perioperative during hospital stay for CABG)

Trial details

NCT IDNCT04309994

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-01

View on ClinicalTrials.gov More Heart Attack trials